For almost 50 years, fecal bile acids have been implicated in playing an important role in colon carcinogenesis. This durable hypothesis has been supported by a variety of lines of evidence drawn from comparisons of the structure of bile acids to various carcinogens, epidemiological studies showing a relationship between increased fecal bile acids and colon cancer prevalence, and more recent studies demonstrating the genotoxic effects of bile acids, particularly for deoxycholic acid the predominant bile acid in stool. Despite such strong evidence linking fecal bile acids and colon cancer the mechanism of bile acid tumor promotion is not understood. Bile acids are known to induce apoptosis and since a critical step in the development of colon tumors is loss of the ability to undergo apoptosis, it has been suggested that bile acids provide a selective pressure that promotes the outgrowth of apoptosis resistant cells. Consequently, the capacity to induce apoptosis is an important activity of bile acids. Related to this, we recently showed that bile acids activate expression of GADD153, a growth arrest and DNA damage gene, that is implicated in regulating cell growth and apoptosis. The focus of this proposal is on determining the relationship between bile acid induced apoptosis, activation of (GADD153 gene expression, and bile acid tumor promotion. The hypotheses to be tested in the proposed studies are that bile acids induce apoptosis by activating the expression of GADD153 and that GADD153 becomes dysregulated in tumor cells.
The specific aims are: 1) identify the cis-acting element in the GADD153 promoter that is responsive to bile acids, 2) identify the signaling pathway by which bile acids cause transactivation of the GADD153 gene and induction of apoptosis in colon cancer cells, 3) determine whether ursodeoxycholic acid, which suppresses tumor development, modifies the expression of GADD153 or the occurrence of apoptosis in preneoplastic aberrant crypt foci and in neoplasms from azoxymethane treated rats and in colonic mucosal samples and neoplasms taken from patients and from subjects treated with ursodeoxycholic acid.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA072008-03S2
Application #
6218888
Study Section
Project Start
1999-07-01
Project End
2000-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Raj, K P; Zell, J A; Rock, C L et al. (2013) Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer 108:512-8
Rial, Nathaniel S; Zell, Jason A; Cohen, Alfred M et al. (2012) Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer. Expert Rev Gastroenterol Hepatol 6:507-17
Laukaitis, Christina M; Erdman, Steven H; Gerner, Eugene W (2012) Chemoprevention in patients with genetic risk of colorectal cancers. Colorectal Cancer 1:225-240
Laukaitis, Christina M; Gerner, Eugene W (2011) DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol 25:495-506
Zell, Jason A; Ziogas, Argyrios; Ignatenko, Natalia et al. (2009) Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res 15:6208-16
Feldman, Rebecca; Martinez, Jesse D (2009) Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. Biochim Biophys Acta 1793:1387-94
Gerner, Eugene W; Meyskens Jr, Frank L (2009) Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res 15:758-61
Rial, Nathaniel S; Lazennec, Gwendal; Prasad, Anil R et al. (2009) Regulation of deoxycholate induction of CXCL8 by the adenomatous polyposis coli gene in colorectal cancer. Int J Cancer 124:2270-80
Zell, Jason A; Pelot, Daniel; Chen, Wen-Pin et al. (2009) Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 2:209-12
Ashbeck, Erin L; Jacobs, Elizabeth T; Martínez, María Elena et al. (2009) Components of metabolic syndrome and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 18:1134-43

Showing the most recent 10 out of 88 publications